---
title: "INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292757743.md"
description: "New research indicates that soluble TNF may play a crucial role in connecting head injuries with Alzheimer’s disease. The study found that targeting soluble TNF with XPro1595 can prevent the increase in amyloid pathology caused by head injuries and also enhance early cognitive function and alleviate pain symptoms. This study highlights the significance of selectively neutralizing soluble TNF in mitigating the impact of head injuries on the development of Alzheimer's disease."
datetime: "2026-07-15T11:03:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292757743.md)
  - [en](https://longbridge.com/en/news/292757743.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292757743.md)
generator: "portal-rs"
---

# INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study

New research indicates that soluble TNF may play a crucial role in connecting head injuries with Alzheimer’s disease. The study found that targeting soluble TNF with XPro1595 can prevent the increase in amyloid pathology caused by head injuries and also enhance early cognitive function and alleviate pain symptoms. This study highlights the significance of selectively neutralizing soluble TNF in mitigating the impact of head injuries on the development of Alzheimer's disease.

### Related Stocks

- [INMB.US](https://longbridge.com/en/quote/INMB.US.md)

## Related News & Research

- [INmune Bio (NASDAQ:INMB) Stock Price Down 1.3%  - What's Next?](https://longbridge.com/en/news/297595042.md)
- [Dogwood Therapeutics highlights Halneuron Phase 2b data readout timeline for chemotherapy-induced neuropathic pain program](https://longbridge.com/en/news/298049944.md)
- [DWTX: Halneuron shows promise as a scalable, effective CINP therapy with strong Phase 2 results](https://longbridge.com/en/news/297686345.md)
- [Autonomix Medical says two transvascular technology abstracts accepted for CIRSE 2026 posters](https://longbridge.com/en/news/297652835.md)
- [Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial](https://longbridge.com/en/news/297812155.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**